RxDoctor Payments Data

Janice Reichert

Psychiatric/Mental Health · Wyomissing, PANPI 1871799148

Payments from drug & device makers

$497in general payments, 2019–2025

Across 23 payments — averaging $21.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$133
  • Johnson & Johnson$70
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$60
  • E.r. Squibb & Sons, L.L.C.$55
  • Neurocrine Biosciences, Inc.$49
  • Otsuka America Pharmaceutical, Inc.$46
  • plus $85 from 3 others

What the payments were for

  • Food & beverage$497100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$497 in reported general payments places this provider in the 50th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

See all psychiatric/mental health providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$20,057
Medicare patients
85
Services billed
237

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole25$34,039
Vilazodone Hcl50$3,764
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine84$3,180
Quetiapine Fumarate171$2,834
Clonazepam257$1,681
Bupropion XlBupropion Hcl74$1,489
Escitalopram Oxalate141$1,460
Divalproex Sodium ErDivalproex Sodium27$1,421
Lamotrigine125$1,359
Mirtazapine54$1,287
Aripiprazole64$1,237
Olanzapine44$1,203
Lorazepam172$1,147
Venlafaxine Hcl ErVenlafaxine Hcl63$1,052
Methylphenidate ErMethylphenidate Hcl18$1,033

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$46$34,03925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

Other psychiatric/mental health in Wyomissing

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →